PAF Receptor and Tumor Growth

Author(s): Sonia Jancar, Roger Chammas

Journal Name: Current Drug Targets

Volume 15 , Issue 10 , 2014

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


The receptor for the lipid mediator PAF (PAFR) is a G-protein coupled receptor expressed in several cell types. Besides PAF, a series of oxidized phospholipids can also bind to PAFR. Dying cells also express PAFR-ligands and, in both situations, scavenger receptors are involved as well. There is evidence that the scavenger receptor CD36 and PAFR associate in the macrophages membrane and signal in conjunction to induce a regulatory phenotype. In the tumor microenvironment, apoptotic cells are abundant due to hypoxia, and PAF-like phospholipids are generated. Engagement of PAFR expressed by tumor macrophages and dendritic cells induces a regulatory/tolerogenic phenotype and subverts the innate and adaptive immune response to the tumor. During cancer therapies, PAFR-ligands can be generated, further aggravating the immune suppression. Moreover, some tumor cells express PAFR and its activation by PAFR-ligands generated during chemotherapy induce anti-apoptotic factors, which protect the tumor cells from death induced by these treatments. It is proposed that PAFR antagonists, administered in combination with chemotherapy, may represent a promising strategy for cancer treatment.

Keywords: Chemotherapy, PAF receptor, tumor growth, tumor macrophages, tumor microenvironment.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 14 September, 2014
Page: [982 - 987]
Pages: 6
DOI: 10.2174/1389450115666140903111812
Price: $65

Article Metrics

PDF: 50